- Home
- CHRS vs MAPS Comparison
CHRS vs MAPS Comparison
Compare CHRS & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MAPS
- Stock Information
- Founded
- CHRS 2010
- MAPS 2008
- Country
- CHRS United States
- MAPS United States
- Employees
- CHRS N/A
- MAPS N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MAPS Computer Software: Prepackaged Software
- Sector
- CHRS Health Care
- MAPS Technology
- Exchange
- CHRS Nasdaq
- MAPS Nasdaq
- Market Cap
- CHRS 112.5M
- MAPS 131.9M
- IPO Year
- CHRS 2014
- MAPS N/A
- Fundamental
- Price
- CHRS $0.76
- MAPS $1.02
- Analyst Decision
- CHRS Buy
- MAPS Strong Buy
- Analyst Count
- CHRS 3
- MAPS 1
- Target Price
- CHRS $4.68
- MAPS $2.61
- AVG Volume (30 Days)
- CHRS 1.2M
- MAPS 614.8K
- Earning Date
- CHRS 08-07-2025
- MAPS 08-07-2025
- Dividend Yield
- CHRS N/A
- MAPS N/A
- EPS Growth
- CHRS N/A
- MAPS N/A
- EPS
- CHRS N/A
- MAPS 0.08
- Revenue
- CHRS $272,251,000.00
- MAPS $184,737,000.00
- Revenue This Year
- CHRS N/A
- MAPS $0.86
- Revenue Next Year
- CHRS $132.69
- MAPS $12.85
- P/E Ratio
- CHRS $1.79
- MAPS $12.50
- Revenue Growth
- CHRS 19.87
- MAPS N/A
- 52 Week Low
- CHRS $0.66
- MAPS $0.70
- 52 Week High
- CHRS $2.43
- MAPS $1.65
- Technical
- Relative Strength Index (RSI)
- CHRS 40.42
- MAPS 41.54
- Support Level
- CHRS $0.74
- MAPS $1.01
- Resistance Level
- CHRS $0.90
- MAPS $1.14
- Average True Range (ATR)
- CHRS 0.05
- MAPS 0.04
- MACD
- CHRS 0.01
- MAPS 0.00
- Stochastic Oscillator
- CHRS 13.56
- MAPS 14.29
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.